Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Cardiol ; 148: 124-129, 2021 06 01.
Article in English | MEDLINE | ID: mdl-33667448

ABSTRACT

The ECG findings during sudden collapse (syncope or sudden death) in severe aortic stenosis (AS) are not well defined. We conducted a comprehensive review of the literature for ECG data during sudden collapse in patients with AS and provided a case report of our own. There were 37 published cases of syncope or sudden death in patients with severe AS which were documented by ECG. Brady- or ventricular arrhythmias were documented in 34 cases (92%). Bradyarrhythmia (n = 24; 71%) was more common at the time of collapse than ventricular tachyarrhythmia (n = 10; 29%). There was slowing of the sinus rate before bradyarrhythmia in the vast majority of patients with bradyarrhythmia but not in those presenting with ventricular tachyarrhythmia (75% vs 0%; p <0.001). ECG evidence of ischemia (ST-segment depression or elevation) was present in most patients with bradyarrhythmia but not in those with ventricular tachyarrhythmia (75% vs 0%; p = 0.011). In conclusion, our findings suggest that left ventricular baroreceptor activation plays a dominant role in the pathophysiology of sudden collapse in patients with severe AS and suggest that ischemia may play a role as well.


Subject(s)
Aortic Valve Stenosis/physiopathology , Bicuspid Aortic Valve Disease/physiopathology , Bradycardia/physiopathology , Death, Sudden, Cardiac , Myocardial Ischemia/physiopathology , Syncope/physiopathology , Tachycardia, Ventricular/physiopathology , Aged , Aortic Valve Stenosis/complications , Bicuspid Aortic Valve Disease/complications , Bradycardia/etiology , Electrocardiography , Heart Ventricles , Humans , Male , Myocardial Ischemia/etiology , Pressoreceptors , Severity of Illness Index , Syncope/etiology , Tachycardia, Ventricular/etiology
4.
J Innov Card Rhythm Manag ; 8(6): 2746-2748, 2017 Jun.
Article in English | MEDLINE | ID: mdl-32494454

ABSTRACT

Cardiac resynchronization therapy is known to improve clinical outcomes in patients with heart failure and left ventricular dyssynchrony. However, the optimal positioning of the right ventricular lead is unknown, and there is conflicting data on the acute hemodynamic effects and long-term outcomes. Here, we present a case of a patient who underwent implantation of a dual-chamber pacemaker for complete heart block, but who after three months, still had symptoms consistent with New York Heart Association (NYHA) Class IV heart failure. After optimal medical therapy failed and a left ventricular lead was placed, he still remained symptomatic, so the right ventricular lead was repositioned from the right ventricular outflow tract to the right ventricular apex. Afterwards, the patient's symptoms improved from NYHA Class IV to NYHA Class II, and his left ventricular ejection fraction improved from 20% to 45%.

6.
Am J Ther ; 23(1): e298-9, 2016.
Article in English | MEDLINE | ID: mdl-24368608

ABSTRACT

Eptifibatide is a commonly and widely used drug for management of acute coronary syndrome and during percutaneous coronary intervention. It is usually well tolerated with no major adverse effects. We report a rare case of life-threatening thrombocytopenia secondary to eptifibatide along with a literature review of available evidence.


Subject(s)
Peptides/adverse effects , Platelet Aggregation Inhibitors/adverse effects , Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors , Thrombocytopenia/chemically induced , Aged , Eptifibatide , Humans , Male
8.
Cardiovasc Drugs Ther ; 29(3): 265-75, 2015 Jun.
Article in English | MEDLINE | ID: mdl-26068409

ABSTRACT

BACKGROUND: Animal studies showed that the use of metformin after myocardial infarction (MI) resulted in a protective effect on cardiac myocytes. In this study, we examined the effect of metformin in patients with diabetes mellitus (DM) on left ventricular ejection fraction (LVEF) and post-MI mortality. METHODS: We reviewed charts of patients with MI admitted to the UAMS medical center. Baseline characteristics and 12-month follow up data were collected. Patients were classified into three groups: Control group- no DM (n = 464), Metformin group- DM + MI (n = 88) and No-Metformin group- DM + MI (n = 168). First, we compared Metformin and No-Metformin groups to the Control group. Second, we performed propensity-score matching in patients with DM, and compared Metformin to No-Metformin groups. RESULTS: All-cause 30-day and 12-month mortality was significantly higher in the No-Metformin group compared to controls (13.5 vs 9.3% p = 0.03 at 30 days, 23.7 vs 15.9 % p = 0.03 at 12 months). However, all-cause 30-day and 12-month mortality were similar in the Controls and Metformin group (9.3 vs 6.8 % p = 0.93 at 30 days, 15.9 vs 11.4 % p = 0.97 at 12 months). Mean LVEF on presentation (45 % in the three groups) and at follow up (47.84, 46.38 and 43.62 % in Control, Metformin, and No-Metformin groups, respectively) were not statistically different. There were no significant differences in regard to re-hospitalization, re-intervention, new stroke, CHF development, new MI, or identifiable arrhythmias. Metformin was an independent predictor of lower 30-day and 12-month all-cause mortality in patients with DM (HR 0.25, p = 0.02 and HR 0.32, p = 0.01, respectively). In the matched analysis, 30-day all-cause mortality was significantly higher in the No-Metformin compared to the Metformin group (21.1 vs 8.8 %, p = 0.05). However the difference in 12-month all-cause mortality did not reach statistical significance (24.6 vs 15.8 %, p = 0.15). CONCLUSION: This proof-of-concept study shows that use of metformin in patients with DM is associated with lower 30-day all-cause mortality and tendency for a lower 12-month all-cause mortality following MI without discernible improvement in LVEF.


Subject(s)
Diabetes Complications/complications , Hypoglycemic Agents/pharmacology , Metformin/pharmacology , Myocardial Infarction/mortality , Stroke Volume/drug effects , Ventricular Function, Left/drug effects , Case-Control Studies , Cause of Death , Diabetes Complications/drug therapy , Diabetes Complications/mortality , Diabetes Complications/physiopathology , Female , Humans , Hypoglycemic Agents/therapeutic use , Male , Metformin/therapeutic use , Middle Aged , Myocardial Infarction/complications , Myocardial Infarction/physiopathology
9.
J Ark Med Soc ; 110(13): 280-3, 2014 Jun.
Article in English | MEDLINE | ID: mdl-25004669

ABSTRACT

We report a case of fatal fulminant hepatic failure related to the use of disulfiram. This is a commonly used medication; however there are few reported cases in the medical literature of fatal liver failure related to its use. Patients using disulfiram for alcohol cessation typically have multiple risk factors for liver disease and are not acutely candidates for orthotopic liver transplant due to recent alcohol dependence. This case demonstrates a rare adverse reaction to a commonly used medication with a fatal outcome. Our patient was a sixty-six year old man who had recently started using disulfiram for the purpose of alcohol cessation. He developed hepatotoxicity that progressed to fulminant hepatic failure. Despite cessation of the medication and supportive care, the outcome was fatal.


Subject(s)
Alcohol Deterrents/adverse effects , Alcoholism/drug therapy , Disulfiram/adverse effects , Liver Failure, Acute/chemically induced , Aged , Fatal Outcome , Humans , Liver Failure, Acute/physiopathology , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...